Ocular Therapeutix (OCUL) EBITDA (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly EBITDA of -$82.1 million for Q2 2026, down 21.39% year-over-year from -$104.5 million in Q2 2025, and up 12.03% on a QoQ basis from -$93.3 million in Q1 2026.
Ocular Therapeutix (OCUL) EBITDA (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported EBITDA for 14 years, with the latest figure at -$82.1 million in Q2 2026.
- EBITDA for Q2 2026 came in at -$82.1 million, down 21.39% year-over-year; the trailing twelve-month figure through Jun 2026 was -$313.9 million (down 37.6% YoY), and the FY2025 annual result was -$270.0 million, down 57.19% from the prior year.
- EBITDA climbed to -$82.1 million in Q2 2026, from -$93.3 million in the prior quarter.
- Over five years, EBITDA peaked at -$17.8 million in Q1 2022 and troughed at -$93.3 million in Q1 2026.
- A 5-year average of -$43.2 million and a median of -$37.6 million in 2024 frame the typical range for EBITDA.
- The widest annual swing landed in 2022, when EBITDA gained 11.84%; it then sank 152.25% in 2024.
- A 5-year view of EBITDA shows it stood at -$19.4 million in 2022, then decreased by 3.56% to -$20.0 million in 2023, then sank by 152.25% to -$50.6 million in 2024, then sank by 37.93% to -$69.8 million in 2025, then retreated by 17.7% to -$82.1 million in 2026.
- Per Business Quant data, the three most recent EBITDA figures were -$82.1 million in Q2 2026, -$93.3 million in Q1 2026, and -$69.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | -82.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -82.11 Mn |
| Mar 31, 2026 | -93.34 Mn |
| Dec 31, 2025 | -69.76 Mn |
| Sep 30, 2025 | -68.70 Mn |
| Jun 30, 2025 | -67.64 Mn |
| Mar 31, 2025 | -63.92 Mn |
| Dec 31, 2024 | -50.58 Mn |
| Sep 30, 2024 | -46.00 Mn |
| Jun 30, 2024 | -43.59 Mn |
| Mar 31, 2024 | -31.62 Mn |
| Dec 31, 2023 | -20.05 Mn |
| Sep 30, 2023 | -19.21 Mn |
| Jun 30, 2023 | -20.57 Mn |
| Mar 31, 2023 | -22.55 Mn |
| Dec 31, 2022 | -19.36 Mn |
| Sep 30, 2022 | -21.54 Mn |
| Jun 30, 2022 | -19.92 Mn |
| Mar 31, 2022 | -17.83 Mn |
| Dec 31, 2021 | -18.05 Mn |
| Sep 30, 2021 | -19.53 Mn |